Characterization of circulating blood dendritic cell subsets DCI23+ (lymphoid) and DCIIC+ (myeloid) in prostate adenocarcinoma patients
Characterization of circulating blood dendritic cell subsets DCI23+ (lymphoid) and DCIIC+ (myeloid) in prostate adenocarcinoma patients
复制标题
DOI：
10.1002/pros.20431
复制
发表时间：
2007-01-01
期刊：
影响因子：
2.8
通讯作者：
Di Silverio, Franco
中科院分区：
文献类型：
--
作者：
Sciarra, Alessandro;Lichtner, Miriam;Di Silverio, Franco
目的。我们验证了前列腺癌在DC亚群计数中是否产生特异性修饰。方法：21例未经治疗的前列腺癌根据局部和转移性疾病的临床分期进行分类。作为对照，我们使用了18名健康的男性受试者。DC计数：所有病例均采集外周血(PB)样本。以Tru计数为基础的单平台流式细胞术用于计数髓系(MDCs)和浆细胞样(PDCs)两种DC亚群。结果：与健康对照组相比，前列腺癌患者的PDCs计数显著减少(P<0.002)。各临床分期与正常对照组比较，前列腺癌患者外周血中DC和MDCs的计数差异均有统计学意义(分别为P=0.005和P=0.023)，而正常对照组和局限性前列腺癌患者的差异无统计学意义(P=0.055和P=0.829)。结论前列腺癌转移患者外周血中DC的数量明显受前列腺癌进展的影响。
PURPOSE. We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count.METHODS. Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs).RESULTS. We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively).CONCLUSIONS. We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease.